Stephanie Kroeze

Dr. Stephanie Kroeze

Department of Radiotherapy, University Hospital Zurich, Zurich, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Cancer Treatment Reviews
Verified
Journal Article
Open access
SKStephanie Kroeze
Stephanie Kroeze
CFCorinna Fritz
Corinna Fritz
MHMorten Høyer
Morten Høyer
SLSimon S. Lo
Simon S. Lo
URUmberto Ricardi
Umberto Ricardi
MGMatthias Guckenberger
Matthias Guckenberger
Both stereotactic radiotherapy (SRT) and immune- or targeted therapy play an increasingly important role in personalized treatment of metastatic disease. Concurrent application of both therapies is rapidly expanding in daily clinical practice. In this systematic review we summarize severe toxicity observed after concurrent treatment. PubMed and EMBASE databases were searched for English literature published up to April 2016 using keywords "radiosurgery", "local ablative therapy", "gamma knife" and "stereotactic", combined with "bevacizumab", "cetuximab", "crizotinib", "erlotinib", "gefitinib", "ipilimumab", "lapatinib", "sorafenib", "sunitinib", "trastuzumab", "vemurafenib", "PLX4032", "panitumumab", "nivolumab", "pembrolizumab", "alectinib", "ceritinib", "dabrafenib", "trametinib", "BRAF", "TKI", "MEK", "PD1", "EGFR", "CTLA-4" or "ALK". Studies performing SRT during or within 30days of targeted/immunotherapy, reporting severe (⩾Grade 3) toxicity were included. Concurrent treatment is mostly well tolerated in cranial SRT, but high rates of severe toxicity were observed for the combination with BRAF-inhibitors. The relatively scarce literature on extra-cranial SRT shows a potential risk of increased toxicity when SRT is combined with EGFR-targeting tyrosine kinase inhibitors and bevacizumab, which was not observed for cranial SRT. This review gives a best-possible overview of current knowledge and its limitations and underlines the need for a timely generation of stronger evidence in this rapidly expanding field.

15 December 2024 in Lung Cancer
Verified
Journal Article
Open access
IHIlias Houda
Ilias Houda
IBIdris Bahce
Idris Bahce
CDChris Dickhoff
Chris Dickhoff
TKTiuri E. Kroese
Tiuri E. Kroese
SKStephanie Kroeze
Stephanie Kroeze
LHLizza Hendriks
Lizza Hendriks
The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials, including a systematic review, survey, and review of clinical cases. Here, the survey results are presented, aimed to identify areas of controversy. A survey was distributed among the members of six international organizations related to lung cancer. Respondents were interrogated on the resectability (not limited to the technical resectability) of all stage III NSCLC TNM-subsets (8th edition). Additionally, four N2-subdivisions were used. The threshold for agreement was 75%. Answers with "yes" were considered upfront resectable. "Yes" and "maybe" were grouped together and considered potentially resectable. Answers with "no" were considered unresectable. 558 responses were collected from thoracic surgeons (38%), radiation oncologists (27%), medical oncologists (17%), pulmonologists (14%), and others (4%). Most worked in a specialized center (80%), had >5 years of experience (80%), were European (76%), male (73%), and treated >20 patients with stage III NSCLC annually (77%). Agreement was found in 26 (70%) out of 37 TNM-subsets: 9 (24%) were considered (potentially) resectable, and 17 (46%) unresectable. There was no agreement for 11 (30%) TNM-subsets: smaller tumors with N2-multistation, larger tumors with N2-single station, and invasive T4-tumors with maximum N2-single station involvement. This international and multidisciplinary survey showed agreement on the resectability for the majority of stage III NSCLC TNM-subsets, but also identified several TNM-subsets for which no agreement was found.

1 March 2021 in European Urology Focus
Verified
Journal Article
Closed access
SKStephanie Kroeze
Stephanie Kroeze
CHChristoph Henkenberens
Christoph Henkenberens
NSNina Sophie Schmidt-Hegemann
Nina Sophie Schmidt-Hegemann
MVMarco M.E. Vogel
Marco M.E. Vogel
SKSimon Kirste
Simon Kirste
MGMatthias Guckenberger
Matthias Guckenberger

6 January 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
SKStephanie Kroeze
Stephanie Kroeze
JSJana Schaule
Jana Schaule
CFCorinna Fritz
Corinna Fritz
DKDavid Kaul
David Kaul
OBOliver Blanck
Oliver Blanck
MGMatthias Guckenberger
Matthias Guckenberger
Background: Metastasis directed treatment (MDT) is increasingly performed with the attempt to improve outcome in non-small cell lung cancer (NSCLC) patients receiving targeted- or immunotherapy (TT/IT). This study aimed to assess the safety and efficacy of metastasis directed stereotactic radiotherapy (SRT) concurrent to TT/IT in NSCLC patients.Methods: A retrospective multicenter cohort of stage IV NSCLC patients treated with TT/IT and concurrent (≤ 30 days) MDT was established. 56% and 44% of patients were treated for oligoprogressive disease (OPD) or polyprogressive disease (PPD) under TT/IT, polyprogressive respectively. Survival was analyzed using Kaplan–Meier and log rank testing. Toxicity was scored using CTCAE v4.03 criteria. Predictive factors for overall survival (OS), progression free survival (PFS) and time to therapy switch (TTS) were analyzed with uni- and multivariate analysis.Results: MDT of 192 lesions in 108 patients was performed between 07/2009 and 05/2018. Concurrent TT/IT consisted of EGFR/ALK-inhibitors (60%), immune checkpoint inhibitors (31%), VEGF-antibodies (8%) and PARP-inhibitors (1%). 2y-OS was 51% for OPD and 25% for PPD. After 1 year, 58% of OPD and 39% of PPD patients remained on the same TT/IT. Second progression after MDT was oligometastatic (≤ 5 lesions) in 59% of patients. Severe acute and late toxicity was observed in 5.5% and 1.9% of patients. In multivariate analysis, OS was influenced by the clinical metastatic status (p = 0.002, HR 2.03, 95% CI 1.30–3.17). PFS was better in patients receiving their first line of systemic treatment (p = 0.033, HR 1.7, 95% CI 1.05–2.77) and with only one metastases-affected organ (p = 0.023, HR 2.04, 95% CI 1.10–3.79). TTS was 6 months longer in patients with one metastases-affected organ (p = 0.031, HR 2.53, 95% CI 1.09–5.89). Death was never therapy-related.Conclusions: Metastases-directed SRT in NSCLC patients can be safely performed concurrent to TT/IT with a low risk of severe toxicity. To find the ideal sequence of the available multidisciplinary treatment options for NSCLC and determine what patients will benefit most, a further evaluated in a broader context within prospective clinical trials is needed continuation of TT/IT beyond progression combined with MDT for progressive lesions appears promising but requires prospective evaluation.Trial registration: retrospectively registered

28 October 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
SKStephanie Kroeze
Stephanie Kroeze
CFCorinna Fritz
Corinna Fritz
JSJana Schaule
Jana Schaule
SSShankar Siva
Shankar Siva
KKKlaus H. Kahl
Klaus H. Kahl
MGMatthias Guckenberger
Matthias Guckenberger

8 February 2019 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
SKStephanie Kroeze
Stephanie Kroeze
CFC. Fritz
C. Fritz
LBL. Basler
L. Basler
EGE. Gkika
E. Gkika
TBThomas Brunner
Thomas Brunner
MGM. Guckenberger
M. Guckenberger